US Patent

US12297189 — Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan

Formulation · Assigned to Idorsia Pharmaceuticals Ltd · Expires 2038-02-26 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel crystalline forms of a specific chemical compound, aprocitentan, and its use as an endothelin receptor antagonist.

USPTO Abstract

The present invention concerns novel crystalline forms of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists. It also relates to new uses of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, either alone or in combination with other active ingredients or therapeutic agents.

Drugs covered by this patent

Patent Metadata

Patent number
US12297189
Jurisdiction
US
Classification
Formulation
Expires
2038-02-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Idorsia Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.